Courier Capital LLC Buys 11,661 Shares of Boston Scientific Co. (NYSE:BSX)

Courier Capital LLC increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 108.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,384 shares of the medical equipment provider’s stock after buying an additional 11,661 shares during the period. Courier Capital LLC’s holdings in Boston Scientific were worth $1,999,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wedbush Securities Inc. acquired a new position in Boston Scientific during the second quarter worth approximately $251,000. BOKF NA lifted its holdings in Boston Scientific by 14.0% during the 2nd quarter. BOKF NA now owns 3,065 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 377 shares during the last quarter. Main Street Financial Solutions LLC bought a new position in Boston Scientific during the second quarter worth $220,000. Oppenheimer & Co. Inc. increased its holdings in shares of Boston Scientific by 7.7% in the second quarter. Oppenheimer & Co. Inc. now owns 75,833 shares of the medical equipment provider’s stock valued at $5,840,000 after purchasing an additional 5,442 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Boston Scientific by 15.3% in the second quarter. Parallel Advisors LLC now owns 11,790 shares of the medical equipment provider’s stock valued at $908,000 after purchasing an additional 1,562 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock worth $2,702,261 in the last quarter. 0.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. TD Cowen raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research note on Friday. Evercore ISI upped their price objective on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Morgan Stanley upped their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Finally, Citigroup lifted their price target on Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.26.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded down $0.10 on Monday, reaching $94.78. The stock had a trading volume of 4,213,238 shares, compared to its average volume of 5,358,167. The business’s 50 day moving average is $89.96 and its two-hundred day moving average is $83.89. The company has a market cap of $139.69 billion, a P/E ratio of 78.33, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $59.61 and a 1 year high of $97.13. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.50 earnings per share. As a group, research analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.